Skip to content
Screener

McKesson MCK North American Pharmaceutical — Total revenues

Other segment segments

Oncology & Multispecialty
$14.22B
Medical-Surgical Solutions
$2.82B+4.4%
Prescription Technology Solutions
$1.57B+9.2%

Similar metrics at other companies

Artivion logo
AORTNorth America — Total revenues
$58.7M+22.8%
Veeva Systems logo
VEEVNorth America — Total revenues
$526.17M+14.5%
PowerFleet, Inc. logo
AIOTNorth America — Total revenues
$39.34M+4.1%
Enviri logo
NVRINorth America — Total revenues
$324.47M-0.8%
ServiceNow logo
NOWNorth America — Total revenues
$2.52B+25.7%
Mirion Technologies logo
MIRNorth America — Total revenues
$179.1M+28.9%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
(In millions)Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Segment revenues (1)
North American Pharmaceutical$86,773$82,729
Oncology & Multispecialty14,22210,658
Prescription Technology Solutions1,5661,434
Medical-Surgical Solutions2,8192,701
Other305
Total revenues$105,380$97,827
Other segment expense, net (2)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's north american pharmaceutical — total revenues?
McKesson (MCK) reported north american pharmaceutical — total revenues of $86.77B in Q2 2026.
How has McKesson's north american pharmaceutical — total revenues changed year-over-year?
McKesson's north american pharmaceutical — total revenues increased by 4.9% year-over-year, from $82.73B to $86.77B.
What is the long-term trend for McKesson's north american pharmaceutical — total revenues?
Over 2 years (2024 to 2026), McKesson's north american pharmaceutical — total revenues has grown at a 13.5% compound annual growth rate (CAGR), from $261.37B to $336.65B.
What does north american pharmaceutical — total revenues mean?
This metric represents the total gross sales generated by the North American Pharmaceutical segment from the distribution of branded, generic, and specialty pharmaceutical products. It serves as the primary top-line indicator for the segment's market share and demand within the healthcare supply chain. This figure is fundamental to assessing the scale and growth trajectory of the company's core wholesale business.

Ask your AI about McKesson's north american pharmaceutical — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude